PCN63 EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION TESTING AND FIRST LINE TREATMENT WITH GEFITINIB IS A DOMINANT STRATEGY IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
May 1, 2011, 00:00
10.1016/j.jval.2011.02.918
https://www.valueinhealthjournal.com/article/S1098-3015(11)01057-6/fulltext
Title :
PCN63 EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION TESTING AND FIRST LINE TREATMENT WITH GEFITINIB IS A DOMINANT STRATEGY IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)01057-6&doi=10.1016/j.jval.2011.02.918
First page :
A166
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
396